ARS regulatory affairs team received licenses for a number of generic drugs manufactured by Russian and Asian pharmaceutical companies: Efavirenz, Nevirapine, Amoxicillin + clavulanic acid, and Losartan potassium + Hydrochlorothiazide. To register the generic pharmaceuticals, the results of local bioequivalence clinical trials conducted in Russia as well as own toxicology preclinical data were submitted to the Russian Ministry of Health.

The ARS contract research organization focuses on single country – Russia and, therefore, has deep local expertise, especially in regulatory matters. The CRO originally comes from drug registration to clinical development operations that makes ARS a highly competitive and competent service provider of clinical research and drug marketing authorization in Russia.